Sorafenib is a widely used multi-kinase inhibitor that targets both the RAF/MEK/ERK pathway and receptor tyrosine kinases, thereby further inhibits tumor growth and angiogenesis in several tumors17. The gene discussed is MAP2K7; the disease is neoplasm.